Search bioRxiv⌕ Search

Biology subjects

Salagianni, M.

Publications and source records attributed to Salagianni, M..

2 recordsLinked to original sources

Polyunsaturated fatty acid-derived lipid mediator networks characterize COVID-19 severity and risk for critical illness

Severe COVID-19, caused by SARS-CoV-2 infection, is characterized by excessive inflammation leading to the development of pneumonia and acute respiratory distress syndrome. Bioactive lipid mediators (LMs) derived from {omega}6 and {omega}3 polyunsaturated fatty acids are central to the regulation of inflammation, controlling both its initiation and resolution. Still, their role in COVID-19 remains underexplored. By employing a holistic approach involving the analysis of white blood cell transcriptomes, targeted lipidomics, cytokine and immune cell profiling, across the spectrum of disease severity groups, including mild non-hospitalized patients and healthy individuals, we now show that LM networks are profoundly altered in COVID-19, correlate with inflammatory patterns, and stratify patients according to disease severity. Central to this are CYP450-derived LMs such as 20-HETE, lipid peroxidation metabolites such as iPF2a-VI, and lipoxygenase-derived LMs such as 12-HETE, all of which are major vasoactive mediators of inflammation. Among them, 20-HETE appears to be a promising prognostic biomarker for ICU admission and a potential therapeutic target for severe COVID-19 disease. Our study thus underscores the significance of LM networks in COVID-19 pathophysiology and sheds light into the broader mechanisms driving viral pneumonia in humans. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=158 SRC="FIGDIR/small/610123v1_ufig1.gif" ALT="Figure 1"> View larger version (69K): org.highwire.dtl.DTLVardef@6e406dorg.highwire.dtl.DTLVardef@47c9deorg.highwire.dtl.DTLVardef@1162488org.highwire.dtl.DTLVardef@b86ba3_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗

Comparative analysis of the effects of retinoic acid versus paclitaxel and everolimus on HL60 cells proliferation and viability.

PurposeAll trans-retinoic acid (atRA) has been proposed as a novel drug for drug eluting stents (DES). Currently complications of DES have been at least partially attributed to the drugs that are used: paclitaxel and sirolimus and its derivatives like everolimus. We compared the effects of atRA, paclitaxel and everolimus on the proliferation and viability of human leukemia cells (HL60). MethodsCells were cultured with 0.1M and 10M of atRA, paclitaxel or everolimus. Cell proliferation and viability was evaluated with trypan blue at 24, 48 and 72 hours. ResultsAll drugs caused a statistically significant, dose-dependent reduction of cell proliferation rate from the first 24 hours. atRA and everolimus did not affect cell viability as the treated cells showed high viability (95-98%), while paclitaxel decreased significantly the viability to below 16% at 72 hours. Unlike the cytotoxic effect of paclitaxel on HL60, atRA demonstrated a cytostatic effect comparable to everolimus. ConclusionThe ability of atRA to limit cell proliferation without affecting cell viability in a manner similar to everolimus, highlights its potential to be used on DES as a novel drug for treatment of restenosis with potentially minimal side-effects. Further research with different cell types, is needed in order to elucidate the possible usefulness of RA on DES.

pharmacology and toxicology↗